Chitosan platelet rich plasma - ChitogenX
Alternative Names: Chitosan PRP-ChitogenX; ORTHO-C; Ortho-C/PRP; ORTHO-M; Ortho-M/PRP; ORTHO-R; Ortho-R/PRP; ORTHO-V; Ortho-V/PRPLatest Information Update: 27 Sep 2023
At a glance
- Originator Ortho Regenerative Technologies
- Developer ChitogenX
- Class Antihaemorrhagics; Antirheumatics; Biopolymers; Cell therapies; Polysaccharides
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Rotator cuff injuries
- Preclinical Cartilage disorders; Ligament injuries; Meniscus disorders; Osteoarthritis; Spinal cord injuries
Most Recent Events
- 27 Sep 2023 ChitogenX completes enrolment in its Phase-I/II trial for Rotator cuff injuries (Adjunctive treatment) in USA
- 29 Sep 2022 ChitogenX receives notice of issuance for ORTHO-R soft tissue repair platform from Canada and the Europe
- 21 Sep 2022 Preclinical trials in Osteoarthritis in USA (Intra-articular) (Chitogenx pipeline, September 2022)